Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade

[1]  P. Van Loo,et al.  Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition , 2021, Cell.

[2]  P. Vandenabeele,et al.  The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses , 2020, Cell Death & Differentiation.

[3]  G. Ayers,et al.  Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity , 2020, Cancer Immunology Research.

[4]  P. Lambin,et al.  A novel co-culture assay to assess anti-tumor CD8+ T cell cytotoxicity via luminescence and multicolor flow cytometry. , 2020, Journal of immunological methods.

[5]  G. Ayers,et al.  Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition , 2020, Clinical Cancer Research.

[6]  Max A. Horlbeck,et al.  Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent , 2020, bioRxiv.

[7]  R. Jain,et al.  Mechanism of action of rigosertib does not involve tubulin binding , 2019, bioRxiv.

[8]  T. Qayyum,et al.  CD40 induces renal cell carcinoma-specific differential regulation of TRAF proteins, ASK1 activation and JNK/p38-mediated, ROS-dependent mitochondrial apoptosis , 2019, Cell Death Discovery.

[9]  R. Dronca,et al.  Immune Checkpoint Inhibitor Toxicities. , 2019, Mayo Clinic proceedings.

[10]  G. Ullenhag,et al.  First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies , 2019, International journal of cancer.

[11]  C. Laymon,et al.  Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma , 2018, The Journal of Nuclear Medicine.

[12]  Monika S. Kowalczyk,et al.  A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade , 2018, Cell.

[13]  J. Ravetch,et al.  Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity , 2018, Proceedings of the National Academy of Sciences.

[14]  G. Ayers,et al.  Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms , 2018, Cancer Immunology Research.

[15]  C. Drake,et al.  Inhibitors of the PD-1 Pathway in Tumor Therapy , 2018, The Journal of Immunology.

[16]  P. Hwu,et al.  Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain , 2017, Nature Communications.

[17]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[18]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[19]  Max A. Horlbeck,et al.  Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent , 2017, Molecular cell.

[20]  A. Bergmann,et al.  An unexpected friend - ROS in apoptosis-induced compensatory proliferation: Implications for regeneration and cancer. , 2017, Seminars in cell & developmental biology.

[21]  H. Tsao,et al.  Somatic driver mutations in melanoma , 2017, Cancer.

[22]  D. Schadendorf,et al.  Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[23]  A. Bergmann,et al.  Killers creating new life: caspases drive apoptosis-induced proliferation in tissue repair and disease , 2017, Cell Death and Differentiation.

[24]  W. Dempke,et al.  Second- and third-generation drugs for immuno-oncology treatment-The more the better? , 2017, European journal of cancer.

[25]  G. Beatty,et al.  Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists , 2017, Expert review of anticancer therapy.

[26]  S. Ikeda,et al.  Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. , 2016, JAMA oncology.

[27]  D. Morrison,et al.  Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit. , 2016, Molecular cell.

[28]  J. Southgate,et al.  A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis , 2016, Oncogene.

[29]  A. Prasad,et al.  ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines , 2016, Oncotarget.

[30]  Liang-Yi Hung,et al.  ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex. , 2016, Translational research : the journal of laboratory and clinical medicine.

[31]  L. Chin,et al.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.

[32]  E. Martínez-Balibrea,et al.  Resistant mechanisms to BRAF inhibitors in melanoma. , 2016, Annals of translational medicine.

[33]  K. Dutta,et al.  A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling , 2016, Cell.

[34]  R. Collins,et al.  Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. , 2016, The Lancet. Oncology.

[35]  G. Beatty,et al.  IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. , 2016, Cancer discovery.

[36]  Shery Jacob,et al.  A simple practice guide for dose conversion between animals and human , 2016, Journal of basic and clinical pharmacy.

[37]  T. Gebhardt,et al.  Skin tumor immunity: Site does matter for antigen presentation by DCs , 2016, European journal of immunology.

[38]  Wenting Liu,et al.  PD-L1 mediated the differentiation of tumor-infiltrating CD19+ B lymphocytes and T cells in Invasive breast cancer , 2016, Oncoimmunology.

[39]  P. Leung,et al.  CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells , 2015, Cell Death and Disease.

[40]  Jen-Yang Tang,et al.  Anticancer drugs for the modulation of endoplasmic reticulum stress and oxidative stress , 2015, Tumor Biology.

[41]  R. Lo,et al.  Vemurafenib resistance reprograms melanoma cells towards glutamine dependence , 2015, Journal of Translational Medicine.

[42]  P. Greenberg,et al.  Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy , 2015, Hematological oncology.

[43]  M. Kataoka,et al.  Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest , 2015, Cancer science.

[44]  C. Weaver,et al.  PD-L1hi B cells are critical regulators of humoral immunity , 2015, Nature Communications.

[45]  J. Berlin,et al.  A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  G. Ayers,et al.  Myeloid IKKβ promotes antitumor immunity by modulating CCL11 and the innate immune response. , 2014, Cancer research.

[47]  Ling Wu,et al.  Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome , 2014, Scientific Reports.

[48]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[49]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[50]  I. Henderson,et al.  B1b Cells Recognize Protective Antigens after Natural Infection and Vaccination , 2014, Front. Immunol..

[51]  J. Sosman,et al.  A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity. , 2014 .

[52]  J. Roboz,et al.  Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. , 2013, American journal of cancer research.

[53]  J. Wolchok.  How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  T. Gilmer,et al.  Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations , 2012, Molecular Cancer Therapeutics.

[55]  A. Wiestner,et al.  ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress , 2012, Clinical Cancer Research.

[56]  A. Eliopoulos,et al.  The death domain kinase RIP1 links the immunoregulatory CD40 receptor to apoptotic signaling in carcinomas , 2011, The Journal of cell biology.

[57]  Enrico Domingo,et al.  BRAF (v-raf murine sarcoma viral oncogene homolog B1) , 2011 .

[58]  A. Ribas,et al.  CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893 , 2010, Journal of immunotherapy.

[59]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[60]  A. Jimeno,et al.  Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[62]  T. Gajewski,et al.  Induction of Cytotoxic Granules in Human Memory CD8+ T Cell Subsets Requires Cell Cycle Progression1 , 2006, The Journal of Immunology.

[63]  A. Blom,et al.  Activation of CD40 in Cervical Carcinoma Cells Facilitates CTL Responses and Augments Chemotherapy-Induced Apoptosis1 , 2004, The Journal of Immunology.

[64]  M. Dallman,et al.  Costimulation of T cells. , 2000, American journal of respiratory and critical care medicine.

[65]  D. Adams,et al.  CD40 Induces Apoptosis in Carcinoma Cells through Activation of Cytotoxic Ligands of the Tumor Necrosis Factor Superfamily , 2000, Molecular and Cellular Biology.

[66]  F. Ionna,et al.  CD40 expressed on human melanoma cells mediates T cell co-stimulation and tumor cell growth. , 2000, International immunology.

[67]  J. Simon,et al.  Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. , 1999, Cancer research.

[68]  James M. Wilson,et al.  CD40 Ligand-Dependent T Cell Activation: Requirement of B7-CD28 Signaling Through CD40 , 1996, Science.

[69]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[70]  Tyler A. Davis,et al.  Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. , 2015, Cancer research.

[71]  Beau Dabbs,et al.  Summary and discussion of : “ Controlling the False Discovery Rate : A Practical and Powerful Approach to Multiple Testing , 2014 .

[72]  F. de Fraipont,et al.  [Mechanisms of resistance to anti-BRAF treatments]. , 2014, Annales de dermatologie et de venereologie.

[73]  J. Southgate,et al.  A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation , 2006, Cell Death and Differentiation.

[74]  A. Tong,et al.  Prospects for CD40-directed experimental therapy of human cancer , 2003, Cancer Gene Therapy.

[75]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..